Safety and Efficacy Study of Bosutinib in Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with one or two more Tyrosine Kinase Inhibitors Primary Objectives •To estimate the 1-year (Week 52) probability of cumulative Major Cytogenetic Response (MCyR) in CP Ph+ CML patients with 1 or 2 prior lines of TKI therapy. •To estimate the 1-yea...

• Country None
• organs None
• Specialty None

A DOUBLE-BLIND, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF PREGABALIN (LYRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES To assess the efficacy of pregabalin as monotherapy in the treatment of patients with partial seizures who are not well controlled on current antiepileptic drug (AED) treatment. Safety data will also ...

• Country None
• organs None
• Specialty None

Étude B7461001 : étude de phase 1-2, évaluant la sécurité d’emploi et l’efficacité de PF-06463922 (inhibiteur de tyrosine kinase ALK/ROS1), chez des patients ayant un cancer bronchique non à petites cellules (CBNPC) avancé présentant des altérations moléculaires spécifiques. L’objectif de cette étude est d’évaluer la sécurité d’emploi et l’efficacité de PF-06463922 (inhibiteur de tyrosine kinase ALK/ROS1), chez des patients ayant un cancer bronchique non à petites cellule...

• Country France
• organs Poumon, type non à petites cellules
• Specialty Thérapies Ciblées

A two part study to a) investigate the reproducilibility of the vaginal photoplethysmograhpy (VPP) teqnique in healthy pre-menopausal volunteers and subjects suffering from Female Sexual Arousal Disorder (FSAD) and b) a randomised double blind, placebo conrolled 4-way crossover study to investigate the effect of single oral doses (10, 50 and 400 mg)of UK-447,841 on vaginal blood flow in pre-menopausal subjects suffering from FSAD Part A: Primary:To investigate the reproducibility of the vaginal photoplethysmography (VPP) technique in healthy pre-menopausal female volunteers and pre-menopausal subjects suffering from FSAD. Pa...

• Country None
• organs None
• Specialty None

Pfizer A3671008 : Essai de phase 2 évaluant l’efficacité et la tolérance d'un traitement par l'anticorps CP-675,206 chez des patients ayant un mélanome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of CP-675,206 in patients with advanced refractory and/or relapsed melanoma.

• Country France
• organs Mélanomes cutanés
• Specialty Thérapies Ciblées

A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS • To compare the efficacy of CP-690,550 (5 mg BID & 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in subjects with moderate to severe chronic ...

• Country None
• organs None
• Specialty None

A randomised, placebo controlled, double blind trial of asenapine in the prevention of relapse after long term treatment of schizophrenia To determine the efficacy of asenapine compared to placebo with respect to the time to an impending relapse in schizophrenia subjects who received treatment with asenapine for 26 weeks.

• Country None
• organs None
• Specialty None

International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer - To compare overall survival (OS) in patients randomized to gemcitabine/cisplatin + PF-3512676 (Investigational Treatment Arm) versus that in patients randomized to gemcitabine/cisplatin alone (Contr...

• Country None
• organs None
• Specialty None

One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera®) on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents. Ensayo abierto de un año y de grupos paralelos para evaluar el impacto de la disponibilidad de insulina a inhalada (Exubera) sobre el control glucémico de pacientes ambulatorios orales To demonstrate that mean reduction in HbA1c after 52 weeks (approx. 12 months) is greater in patients to whom inhaled insulin is made available compared to patients to whom it is not.

• Country None
• organs None
• Specialty None

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS To determine the efficacy of PF-04171327 (high and low dose) compared to placebo as assessed by DAS28-4 (CRP) at Week 2

• Country None
• organs None
• Specialty None